Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

× No keyword cloud information.

31 in total

Review 1. Paramyxovirus reverse genetics is coming of age.

Authors: Y Nagai; A Kato
Journal: Microbiol Immunol Date: 1999 Impact factor: 1.955

Review 2. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.

Authors: P L Collins; S S Whitehead; A Bukreyev; R Fearns; M N Teng; K Juhasz; R M Chanock; B R Murphy
Journal: Adv Virus Res Date: 1999 Impact factor: 9.937

3. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.

Authors: T Tao; F Davoodi; C J Cho; M H Skiadopoulos; A P Durbin; P L Collins; B R Murphy
Journal: Vaccine Date: 2000-01-31 Impact factor: 3.641

4. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.

Authors: M H Skiadopoulos; S R Surman; A P Durbin; P L Collins; B R Murphy
Journal: Virology Date: 2000-06-20 Impact factor: 3.616

5. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents.

Authors: H Jin; X Cheng; H Z Zhou; S Li; A Seddiqui
Journal: J Virol Date: 2000-01 Impact factor: 5.103

6. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.

Authors: J E Bailly; J M McAuliffe; A P Durbin; W R Elkins; P L Collins; B R Murphy
Journal: J Virol Date: 2000-04 Impact factor: 5.103

7. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.

Authors: A C Schmidt; J M McAuliffe; A Huang; S R Surman; J E Bailly; W R Elkins; P L Collins; B R Murphy; M H Skiadopoulos
Journal: J Virol Date: 2000-10 Impact factor: 5.103

8. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.

Authors: M N Teng; S S Whitehead; A Bermingham; M St Claire; W R Elkins; B R Murphy; P L Collins
Journal: J Virol Date: 2000-10 Impact factor: 5.103

9. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo.

Authors: H Jin; H Zhou; X Cheng; R Tang; M Munoz; N Nguyen
Journal: Virology Date: 2000-07-20 Impact factor: 3.616

10. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Authors: P F Wright; R A Karron; R B Belshe; J Thompson; J E Crowe; T G Boyce; L L Halburnt; G W Reed; S S Whitehead; E L Anderson; A E Wittek; R Casey; M Eichelberger; B Thumar; V B Randolph; S A Udem; R M Chanock; B R Murphy
Journal: J Infect Dis Date: 2000-09-22 Impact factor: 5.226

34 in total

1. New directions in vaccine research.

Authors: Peter Palese; Adolfo García-Sastre
Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808

2. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors: Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal: J Virol Date: 2004-02 Impact factor: 5.103

Review 3. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors: Yechiel Becker
Journal: Virus Genes Date: 2006-10 Impact factor: 2.332

Review 4. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors: Peter L Collins; Brian R Murphy
Journal: Proc Am Thorac Soc Date: 2005

Review 5. Animal pneumoviruses: molecular genetics and pathogenesis.

Authors: Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal: Clin Microbiol Rev Date: 2004-04 Impact factor: 26.132

Review 6. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors: José A Melero; Vicente Mas; Jason S McLellan
Journal: Vaccine Date: 2016-09-28 Impact factor: 3.641

7. Respiratory syncytial virus vaccine: Is it coming?

Authors: Valérie Sales; Elaine El Wang
Journal: Paediatr Child Health Date: 2003-12 Impact factor: 2.253

8. Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA.

Authors: Sander Herfst; Miranda de Graaf; Jeanne H Schickli; Roderick S Tang; Jasmine Kaur; Chin-Fen Yang; Richard R Spaete; Aurelia A Haller; Bernadette G van den Hoogen; Albert D M E Osterhaus; Ron A M Fouchier
Journal: J Virol Date: 2004-08 Impact factor: 5.103

9. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors: Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal: PLoS Biol Date: 2009-07-21 Impact factor: 8.029

10. Anticancer oncolytic activity of respiratory syncytial virus.

Authors: I Echchgadda; S Kota; I DeLa Cruz; A Sabbah; T Chang; R Harnack; V Mgbemena; B Chatterjee; S Bose
Journal: Cancer Gene Ther Date: 2009-05-15 Impact factor: 5.987